Important note

This AI stock analysis for Gilead Sciences is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Gilead Sciences - AI Stock Analysis

Analysis generated March 11, 2025

Gilead Sciences, Inc. is an American biopharmaceutical company that focuses on the research, development, and commercialization of treatments for life-threatening diseases. Founded in 1987 and headquartered in Foster City, California, Gilead has grown into a prominent player in the biotechnology industry. The company’s portfolio includes treatments for HIV/AIDS, liver diseases, cancer, and inflammatory diseases. Gilead is known for its innovative approach to drug development, making it a key player in the healthcare sector.

Fundamental Analysis

When examining the fundamentals of Gilead Sciences, several insights can be derived from recent financial data:

• Revenue: The revenue for the last quarter was $7.54 billion. This represents an increase of 8.00% from the previous quarter and an increase of 10.68% year-over-year. A consistent rise in revenue is a positive indicator of growth potential, showing the company’s ability to generate sales.
• Net Income: The net income for the last quarter was $1.25 billion, a decrease of 22.37% compared to the previous quarter and a startling decrease of 42.52% year-over-year. While revenue is rising, the significant drop in net income might indicate increasing costs or trouble in operational efficiency.
• EBITDA: The EBITDA for the last quarter was $1.88 billion, representing a decrease of 36.84% quarter-over-quarter and a 40.30% year-over-year drop. A declining EBITDA further underscores the profitability concerns hinted at by the net income figures.
• P/E Ratio: Currently sitting at 308.97, this high P/E ratio suggests that Gilead might be overvalued at its existing price level. Usually, a very high P/E ratio can imply a bearish outlook as investors may expect higher earnings growth than it is possible.

In addition, insider selling in recent months could be perceived as a bearish signal, reflecting a lack of confidence in the stock’s future performance from those within the company.

Technical Analysis

Analyzing the stock's technical indicators gives insight into its short-term and long-term trends:

• Stock Price: As of today, the stock price is $116.05, marking a 20.71% increase from a month ago and a significant 60.82% increase year-over-year. This reveals a strong upward trend for the stock in both the short term and the long term.
• SMA (Simple Moving Average): The current SMA10 is $116.20, up from the previous SMA10 of $116.03. This slight increase is a potential indicator of an upward price trend, reaffirming bullish movements in the stock.
• RSI (Relative Strength Index): The RSI stands at 31.1, indicating a neutral condition. Being close to the lower end of the typical RSI range (30-70) suggests that the stock is neither overbought nor oversold.

Overall, the technical analysis points to a bullish trend with positive price movement.

Alternative Data Analysis

Digging deeper into alternative data provides an additional layer of insight:

• Job Postings and Employee Sentiment: Gilead Sciences currently has 156 open positions, a decrease of 57% over the last couple of months. This substantial decline may indicate cost-cutting measures or efficiency improvements but poses concern if driven by reduced business activity.
• Business Outlook: Employee sentiment remains neutral, suggesting neither overwhelmingly positive nor negative feelings about the company's future.
• Customer Acquisition: The company website receives approximately 400,000 visitors per month, a stable figure that shows no significant growth or decline in customer interest.
• Customer Engagement: Gilead's Twitter account has 73,000 followers—a 1% decrease over the past couple of months, indicating a slight decline in public interest or engagement.
• AI Stock Prediction: According to AltIndex’s AI score, Gilead Sciences has an AI score of 44, assigning it a “hold” signal, suggesting market watchers neither strongly favor buying nor selling the stock at present.

Conclusion and Recommendation

Gilead Sciences presents a mixed bag of indicators. On the one hand, the company shows strong revenue growth and a bullish stock trend indicating market confidence. However, the significant declines in net income and EBITDA, along with insider selling and cautious alternative data, raise some flags. With a high P/E ratio and neutral employee sentiment, the cautious outlook on the stock is further supported.

While the stock shows strong upward momentum and growth potential in revenue, it is wise to exercise caution due to the concerning profitability metrics and internal signals. Given these mixed signals, a prudent recommendation would be to hold on Gilead Sciences' stock, awaiting clearer signs of long-term stability and profitability.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.